<DOC>
	<DOCNO>NCT00262925</DOCNO>
	<brief_summary>This phase II trial study well give combination chemotherapy together alemtuzumab work treat patient relapsed refractory acute lymphoblastic leukemia . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Monoclonal antibody , alemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving combination chemotherapy together alemtuzumab may kill cancer cell .</brief_summary>
	<brief_title>Combination Chemotherapy Alemtuzumab Treating Patients With Relapsed Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete response rate patient relapse refractory acute lymphoblastic leukemia treat methotrexate , vincristine , asparaginase , dexamethasone ( MOAB ) combination alemtuzumab . II . Determine disease-free and/or overall survival patient treat regimen . III . Determine toxic effect regimen patient . IV . Correlate density cluster differentiation 52 ( CD52 ) molecules surface leukemic lymphoblast response patient treat regimen . V. Correlate presence minimal residual disease time maximal response regimen overall outcome patient . OUTLINE : This multicenter study . The study two step . Step 1 : 5 mg dose Campath ( alemtuzumab ) ; Step 2 : 10 mg dose Campath . INDUCTION THERAPY : Patients receive methotrexate intravenously ( IV ) day 1 ; vincristine IV asparaginase intramuscularly ( IM ) day 2 ; oral dexamethasone day 1-10 ; alemtuzumab subcutaneously ( SC ) day 1 , 4 , 7 . Treatment repeat every 10 day 6 course absence disease progression unacceptable toxicity . Patients achieve complete remission ( CR ) proceed consolidation therapy . CONSOLIDATION THERAPY : Patients receive methotrexate IV day 1 asparaginase IM day 2 . Treatment repeat every 10 day 6 course absence disease progression unacceptable toxicity . Patients remain CR proceed cytoreduction therapy . CYTOREDUCTION THERAPY : Patients receive vincristine IV methotrexate IV 6 hour day 1 ; leucovorin calcium IV continuously 24 hour day 1 2 orally 4 time day day 3 ; oral dexamethasone day 2-6 . Treatment repeat every 30 day 12 course absence disease progression unacceptable toxicity . Patients remain CR proceed maintenance therapy . MAINTENANCE THERAPY : Patients receive oral mercaptopurine day 1-30 ; oral methotrexate day 1 , 8 , 15 , 22 ; vincristine IV day 1 ; oral dexamethasone day 1-5 . Treatment repeat every 30 day 36 course absence disease progression unacceptable toxicity . Patients assess every 3 month patient &lt; 2 year study entry every 6 month patient 2-5 year study entry . PROJECTED ACCRUAL : Allowing two dose level , maximum 48 patient may accrue approximately 30 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Refractory relapse acute lymphoblastic leukemia Must first relapse fail achieve complete remission 1 prior regimen Prior central nervous system ( CNS ) leukemia allow provide cerebrospinal fluid normal ECOG Performance status 03 Bilirubin normal Creatinine normal Human immunodeficiency virus ( HIV ) negative Negative pregnancy test Fertile patient must use effective contraception Exclusion criterion : Hepatitis B positivity Bacterial fungal infection Infection require treatment antibiotic Active cytomegalovirus infection molecular detection method Known hypersensitivity alemtuzumab component Pregnant nursing Other malignancy within past 5 year except adequately treat basal cell skin cancer cervical carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>MOAD</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Vincristine</keyword>
	<keyword>L-asparaginase</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Subcutaneous Campath</keyword>
</DOC>